simmitecan / HaiHe Biopharma, Shanghai Inst. of Materia Medica - LARVOL DELTA

A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor. (PubMed, Front Pharmacol) - "The majority of patients (24/41, 58.3%) had progressed on prior irinotecan; nevertheless, partial response was achieved in one colorectal cancer patients treated with simmitecan + thalidomide. Simmitecan + 5-FU/LV regimen seemed to have a better efficacy. Nonetheless, the efficacy of this regimen needs to be further explored in the subsequent study."

Combination therapy • Journal • P1 data • Colorectal Cancer • Febrile Neutropenia • Gastrointestinal Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • TOP1

A validated HPLC-MS/MS method for determination of simmitecan and its metabolite chimmitecan in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. (PubMed, J Sep Sci) - "Both irinotecan and 7-ethyl-10-hydroxycamptothecin were used as the internal standards. The accuracies were 99.4-103.5% for simmitecan and 95.4-103.5% for chimmitecan. This method was further successfully applied to a pharmacokinetic study of simmitecan in Chinese advanced solid cancer patients after administration of simmitecan hydrochloride injection."

Clinical • Journal • PK/PD data • Oncology • Solid Tumor